Biogen Inc.: Biogen Submits Final Protocol for ADUHELM (aducanumab-avwa) Phase 4 ENVISION Trial to FDA
Confirmatory trial's completion is expected in an accelerated timeline of four years with patient screening to start in MayMultiple strategies in place to enroll patients that are representative of diverse
Source: finanznachrichten.de